TVGN (Tevogen Bio Holdings) Debt-to-Asset : 0.83 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Debt-to-Asset?

Tevogen Bio Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1.88 Mil. Tevogen Bio Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1.01 Mil. Tevogen Bio Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $3.46 Mil. Tevogen Bio Holdings's debt to asset for the quarter that ended in Dec. 2024 was 0.83.

Tevogen Bio Holdings Debt-to-Asset Historical Data

The historical data trend for Tevogen Bio Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Debt-to-Asset Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

3.07

17.33

0.83

Tevogen Bio Holdings Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial					17.33	0.62	0.61	0.69	0.83

Competitive Comparison of Tevogen Bio Holdings's Debt-to-Asset

For the Biotechnology subindustry, Tevogen Bio Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tevogen Bio Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tevogen Bio Holdings's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Tevogen Bio Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tevogen Bio Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.88	+	1.006)	/	3.462
	=	0.83

Tevogen Bio Holdings's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.88	+	1.006)	/	3.462
	=	0.83

Tevogen Bio Holdings (NAS:TVGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tevogen Bio Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (NAS:TVGN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.